|
1
|
Vestergaard HH, Christensen MR and Lassen
UN: A systematic review of targeted agents for non-small cell lung
cancer. Acta Oncol. 57:176–186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiong Y, Wang T, Wang M, Zhao J, Li X,
Zhang Z, Zhou Y, Liu J, Jia L and Han Y: Long non-coding RNAs
function as novel predictors and targets of non-small cell lung
cancer: A systematic review and meta-analysis. Oncotarget.
9:11377–11386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gentilin E, Degli Uberti E and Zatelli MC:
Strategies to use microRNAs as therapeutic targets. Best Pract Res
Clin Endocrinol Metab. 30:629–639. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma R, Wang C, Wang J, Wang D and Xu J:
miRNA-mRNA interaction network in non-small-cell lung cancer.
Interdiscip Sci. 8:209–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang W, Zhang Q, Zhang M, Zhang Y, Li F
and Lei P: Analysis for the mechanism between the small cell lung
cancer and non-small cell lung cancer combing the miRNA and mRNA
expression profiles. Thorac Cancer. 6:70–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu T, Liu L, Li J, Yan M, Lin H, Liu Y,
Chu D, Tu H, Gu A and Yao M: MiRNA-10a is upregulated in NSCLC and
may promote cancer by targeting PTEN. Oncotarget. 6:30239–30250.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L,
Huang H, Li S and Zhao J: MiRNA 17 family regulates
cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
PLoS One. 9:e946392014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F
and Li D: MicroRNA-187-3p mitigates non-small cell lung cancer
(NSCLC) development through down-regulation of BCL6. Biochem
Biophys Res Commun. 471:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei WF, Zhou CF, Wu XG, He LN, Wu LF, Chen
XJ, Yan RM, Zhong M, Yu YH, Liang L and Wang W: MicroRNA-221-3p, a
TWIST2 target, promotes cervical cancer metastasis by directly
targeting THBS2. Cell Death Dis. 8:32202017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li F, Xu JW, Wang L, Liu H, Yan Y and Hu
SY: MicroRNA-221-3p is up-regulated and serves as a potential
biomarker in pancreatic cancer. Artif Cells Nanomed Biotechnol.
46:482–487. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi J, Zhang Y, Jin N, Li Y, Wu S and Xu
L: MicroRNA-221-3p plays an oncogenic role in gastric carcinoma by
inhibiting PTEN expression. Oncol Res. 25:523–536. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng L, Lei Q, Wang Y, Wang Z, Xie G,
Zhong X, Wang Y, Chen N, Qiu Y, Pu T, et al: Downregulation of
miR-221-3p and upregulation of its target gene PARP1 are prognostic
biomarkers for triple negative breast cancer patients and
associated with poor prognosis. Oncotarget. 8:108712–108725. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garofalo M, Quintavalle C, Romano G, Croce
CM and Condorelli G: miR221/222 in cancer: Their role in tumor
progression and response to therapy. Curr Mol Med. 12:27–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yi Y, Zhao Y, Li C, Zhang L, Huang H, Li
Y, Liu L, Hou P, Cui T, Tan P, et al: RAID v2.0: An updated
resource of RNA-associated interactions across organisms. Nucleic
Acids Res. 45:D115–D118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Raghu D, Paul PJ, Gulati T, Deb S, Khoo C,
Russo A, Gallo E, Blandino G, Chan AL, Takano E, et al: E6AP
promotes prostate cancer by reducing p27 expression. Oncotarget.
8:42939–42948. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vasile Bochis O, Achimas-Cadariu P, Vlad
C, Fetica B, Corneliu Leucuta D, Ioan Busuioc C and Irimie A: The
prognostic role of Skp2 and the tumor suppressor protein p27 in
colorectal cancer. J BUON. 22:1122–1130. 2017.PubMed/NCBI
|
|
24
|
Ventura C, Nunez M, Gaido V, Pontillo C,
Miret N, Randi A and Cocca C: Hexachlorobenzene alters cell cycle
by regulating p27-cyclin E-CDK2 and c-Src-p27 protein complexes.
Toxicol Lett. 270:72–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garofalo M, Quintavalle C, Di Leva G,
Zanca C, Romano G, Taccioli C, Liu CG, Croce CM and Condorelli G:
MicroRNA signatures of TRAIL resistance in human non-small cell
lung cancer. Oncogene. 27:3845–3855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou CF, Ma J, Huang L, Yi HY, Zhang YM,
Wu XG, Yan RM, Liang L, Zhong M, Yu YH, et al: Cervical squamous
cell carcinoma-secreted exosomal miR-221-3p promotes
lymphangiogenesis and lymphatic metastasis by targeting VASH1.
Oncogene. 38:1256–1268. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu Q, Ren X, Zhang Y, Fu X, Li Y, Peng Y,
Xiao Q, Li T, Ouyang C, Hu Y, et al: MiR-221-3p targets ARF4 and
inhibits the proliferation and migration of epithelial ovarian
cancer cells. Biochem Biophys Res Commun. 497:1162–1170. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu D, Huang Y, Kang J, Li K, Bi X, Zhang
T, Jin N, Hu Y, Tan P, Zhang L, et al: ncRDeathDB: A comprehensive
bioinformatics resource for deciphering network organization of the
ncRNA-mediated cell death system. Autophagy. 11:1917–1926. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sgambato A, Cittadini A, Faraglia B and
Weinstein IB: Multiple functions of p27(Kip1) and its alterations
in tumor cells: A review. J Cell Physiol. 183:18–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guan X, Wang Y, Xie R, Chen L, Bai J, Lu J
and Kuo MT: p27(Kip1) as a prognostic factor in breast cancer: A
systematic review and meta-analysis. J Cell Mol Med. 14:944–953.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Borriello A, Bencivenga D, Criscuolo M,
Caldarelli I, Cucciolla V, Tramontano A, Borgia A, Spina A, Oliva
A, Naviglio S and Della Ragione F: Targeting p27Kip1 protein: Its
relevance in the therapy of human cancer. Expert Opin Ther Targets.
15:677–693. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wander SA, Zhao D and Slingerland JM: p27:
A barometer of signaling deregulation and potential predictor of
response to targeted therapies. Clin Cancer Res. 17:12–18. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sharma SS and Pledger WJ: The
non-canonical functions of p27(Kip1) in normal and tumor biology.
Cell Cycle. 15:1189–1201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fernandez S, Risolino M and Verde P: A
novel miRNA-mediated STOP sign in lung cancer: miR-340 inhibits the
proliferation of lung cancer cells through p27(KIP1). Mol Cell
Oncol. 2:e9771472015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang C, Ba X, Guo Y, Sun D, Jiang H, Li W,
Huang Z, Zhou G, Wu S, Zhang J and Chen J: MicroRNA-199a-5p
promotes tumour growth by dual-targeting PIAS3 and p27 in human
osteosarcoma. Sci Rep. 7:414562017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Zeng J, Pan J, Geng X, Liu Y, Wu
J, Song P, Wang Y, Jia J and Wang L: MicroRNA-200c is involved in
proliferation of gastric cancer by directly repressing p27(Kip1).
Biochem Biophys Rep. 8:227–233. 2016.PubMed/NCBI
|
|
37
|
Yang YF, Wang F, Xiao JJ, Song Y, Zhao YY,
Cao Y, Bei YH and Yang CQ: MiR-222 overexpression promotes
proliferation of human hepatocellular carcinoma HepG2 cells by
downregulating p27. Int J Clin Exp Med. 7:893–902. 2014.PubMed/NCBI
|
|
38
|
Sarkar S, Dubaybo H, Ali S, Goncalves P,
Kollepara SL, Sethi S, Philip PA and Li Y: Down-regulation of
miR-221 inhibits proliferation of pancreatic cancer cells through
up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer
Res. 3:465–477. 2013.PubMed/NCBI
|
|
39
|
Zhang T, Tan P, Wang L, Jin N, Li Y, Zhang
L, Yang H, Hu Z, Zhang L, Hu C, et al: RNALocate: A resource for
RNA subcellular localizations. Nucleic Acids Res. 45:D135–D138.
2017.PubMed/NCBI
|
|
40
|
Cui T, Zhang L, Huang Y, Yi Y, Tan P, Zhao
Y, Hu Y, Xu L, Li E and Wang D: MNDR v2.0: An updated resource of
ncRNA-disease associations in mammals. Nucleic Acids Res.
46:D371–D374. 2018.PubMed/NCBI
|
|
41
|
Li Y, Wang C, Miao Z, Bi X, Wu D, Jin N,
Wang L, Wu H, Qian K, Li C, et al: ViRBase: A resource for
virus-host ncRNA-associated interactions. Nucleic Acids Res.
43:D578–D582. 2015. View Article : Google Scholar : PubMed/NCBI
|
